Diabetes

Benefits of Intensive SBP Treatment Extend to Patients WIth Prediabetes

Benefits of Intensive SBP Treatment Extend to Patients WIth Prediabetes

The beneficial effects of intensive systolic blood pressure treatment are similar among those with prediabetes and fasting normoglycemia.

Insulin Initiation Associated With Weight Gain, Acitvity Decreases in T2D

Insulin Initiation Associated With Weight Gain, Acitvity Decreases in T2D

By

Initiation of insulin therapy in patients with type 2 diabetes was associated to inactivity and weight gain.

Hypertension, Diabetes in Midlife Increase Risk of Dementia

Hypertension, Diabetes in Midlife Increase Risk of Dementia

Risk factors for dementia include midlife vascular risk factors such as hypertension, diabetes and smoking.

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

By

Patients with psoriasis have high rates of cardiometabolic comorbidities.

Increases in NT-proBNP and hsTnI Delayed in Type 2 Diabetes With Canagliflozin

Increases in NT-proBNP and hsTnI Delayed in Type 2 Diabetes With Canagliflozin

Canagliflozin delayed the rise in several cardiac biomarkers for over 2 years in older type 2 diabetes patients patients.

FDA Approves Pitavastatin as Adjunctive Therapy for Hyperlipidemia or Mixed Dyslipidemia

FDA Approves Pitavastatin as Adjunctive Therapy for Hyperlipidemia or Mixed Dyslipidemia

By

The FDA has approved Zypitamag for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia.

Left Ventricular Function in Type 1 Diabetes Improves With Exercise

Left Ventricular Function in Type 1 Diabetes Improves With Exercise

Adolescents with type 1 diabetes may benefit from a 20 week exercise training intervention that's associated with improved aerobic capacity and stroke volume.

Diabetes Increases Hospital Readmissions Rates

Diabetes Increases Hospital Readmissions Rates

By

Patients with diabetes had a higher rate of readmission to hospitals compared with patients without diabetes.

Two-Hour Postload Glucose Predicts CV Events Better Than Fasting Glucose, HbA1C

Two-Hour Postload Glucose Predicts CV Events Better Than Fasting Glucose, HbA1C

By

Two-hour postload glucose (2h-PG) may be a better predictor of cardiovascular events in patients with coronary artery disease.

Heart Failure in Type 2 Diabetes: Improving the Risk Model

Heart Failure in Type 2 Diabetes: Improving the Risk Model

By

N-terminal pro-B-type natriuretic peptide showed the strongest association with heart failure in patients with type 2 diabetes.

Cardiovascular Risk in Type 2 Diabetes Reduced With Electronic Messaging

Cardiovascular Risk in Type 2 Diabetes Reduced With Electronic Messaging

An electronic messaging intervention is effective for reducing cardiovascular risk for patients with type 2 diabetes.

FDA Tentatively Approves Follow-On Biologic Basal Insulin Glargine

FDA Tentatively Approves Follow-On Biologic Basal Insulin Glargine

Tentative FDA approval has been granted to Merck's follow-on biologic basal insulin injection, Lusduna Nexvue.

CVD Risk in Diabetes Predicted by Visceral to Subcutaneous Fat Area Ratio

CVD Risk in Diabetes Predicted by Visceral to Subcutaneous Fat Area Ratio

In patients with increasing visceral to subcutaneous fat area ratio quartiles, there were more first or recurring cardiovascular disease.

Major Cardiovascular Events in Diabetes Predicted Coronary CT Angiography

Major Cardiovascular Events in Diabetes Predicted Coronary CT Angiography

CCTA-detected obstructive coronary artery disease (CAD) improves prediction of MACE in patients with type 2 diabetes.

Glycemic Control Improves With Hepatitis C Treatment

Glycemic Control Improves With Hepatitis C Treatment

Direct-acting antiviral treatment for hepatitis C virus is linked to improved glycemic control in patients with type 2 diabetes.

Chronic Inflammatory Disorders Increase Cardiometabolic and Mortality Risks

Chronic Inflammatory Disorders Increase Cardiometabolic and Mortality Risks

By

The degree of risk for cardiometabolic events and all-cause mortality increased with nonsteroidal anti-inflammatory drugs and corticosteroid drugs.

Blood Pressure Reductions With SGLT2 Inhibitors in Type 2 Diabetes

Blood Pressure Reductions With SGLT2 Inhibitors in Type 2 Diabetes

By

Sodium-glucose cotransporter 2 inhibitors produce an off-target effect on blood pressure in type 2 diabetes patients.

CVD Risk in Type 1 Diabetes Improved With Metformin

CVD Risk in Type 1 Diabetes Improved With Metformin

By

Metformin therapy in type 1 diabetes may improved cardiovascular disease risk management.

CV Events, Death in Diabetes vs No Diabetes Without Coronary Artery Disease

CV Events, Death in Diabetes vs No Diabetes Without Coronary Artery Disease

Without obstructive coronary artery disease, adjusted risk of death, cardiac death, and myocardial infarction was the same in patients with or without diabetes.

FDA to Review Insulin Degludec for Cardiovascular Safety

FDA to Review Insulin Degludec for Cardiovascular Safety

By

Novo Nordisk submitted an application to the FDA with data on the cardiovascular safety of an insulin degludec.

PCSK9 Inhibitor Trends in Type 1 Diabetes

PCSK9 Inhibitor Trends in Type 1 Diabetes

PCSK9 had a significant correlation with hemoglobin A1c, triglycerides, total cholesterol, LDL cholesterol, and apolipoprotein B in patients with type 1 diabetes.

Cardiovascular Disease May Benefit From Chinese Medicine

Cardiovascular Disease May Benefit From Chinese Medicine

Herbal alternatives used in traditional Chinese medicine may help treat or prevent cardiovascular disease.

Systolic Blood Pressure Variability Independently Predicts CV Events and Death in Diabetes

Systolic Blood Pressure Variability Independently Predicts CV Events and Death in Diabetes

By

Visit-to-visit systolic blood pressure variability may be a better predictor of cardiovascular events and death than traditional risk factors.

Statins May Increase Risk for Mortality in Type 2 Diabetes

Statins May Increase Risk for Mortality in Type 2 Diabetes

By

In a study,patients with type 2 diabetes presented better glycemic control and had higher risk for mortality when not taking statins.

Cardiovascular Stress in Type 2 Diabetes Reduced With Canagliflozin

Cardiovascular Stress in Type 2 Diabetes Reduced With Canagliflozin

By

American Diabetes Association presented a study that Canagliflozin could possibly decrease cardiovascular stress in older patients with type 2 diabetes.

Cardiovascular Events Reduced With Intensive Blood Pressure Control

Cardiovascular Events Reduced With Intensive Blood Pressure Control

By

Intensive systolic blood pressure treatment outcomes were similar between groups of patients with prediabetes and with normal fasting blood glucose levels.

CV Risks in Obesity and Diabetes Not Increased With Nalxtrexone/Bupropion

CV Risks in Obesity and Diabetes Not Increased With Nalxtrexone/Bupropion

By

Two studies found that extended-release naltrexone/bupropion did not increase cardiovascular risks for patients with type 2 diabetes.

Intensive Glucose Control in Diabetes Reduces Kidney and Eye Events

Intensive Glucose Control in Diabetes Reduces Kidney and Eye Events

By

Kidney and eye events in type 2 diabetes were reduced with more intensive glucose control.

Refill Synchronization Beneficial for Medication Adherence

Refill Synchronization Beneficial for Medication Adherence

Appointment-based models improve medication-taking behavior.

Assessing Mortality Risks in CVD, T2DM vs CKD

Assessing Mortality Risks in CVD, T2DM vs CKD

By

Chronic kidney increases the risk of mortality in patients with cardiovascular disease.

Sign Up for Free e-Newsletters